90 related articles for article (PubMed ID: 24913694)
1. Targeting breast cancer initiating cells: advances in breast cancer research and therapy.
McCubrey JA; Davis NM; Abrams SL; Montalto G; Cervello M; Libra M; Nicoletti F; D'Assoro AB; Cocco L; Martelli AM; Steelman LS
Adv Biol Regul; 2014 Sep; 56():81-107. PubMed ID: 24913694
[TBL] [Abstract][Full Text] [Related]
2. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.
McCubrey JA; Abrams SL; Fitzgerald TL; Cocco L; Martelli AM; Montalto G; Cervello M; Scalisi A; Candido S; Libra M; Steelman LS
Adv Biol Regul; 2015 Jan; 57():75-101. PubMed ID: 25453219
[TBL] [Abstract][Full Text] [Related]
3. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
4. Targeting the cancer initiating cell: the ultimate target for cancer therapy.
McCubrey JA; Steelman LS; Abrams SL; Misaghian N; Chappell WH; Basecke J; Nicoletti F; Libra M; Ligresti G; Stivala F; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Bonati A; Evangelisti C; Cocco L; Martelli AM
Curr Pharm Des; 2012; 18(13):1784-95. PubMed ID: 22394167
[TBL] [Abstract][Full Text] [Related]
5. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
6. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
[TBL] [Abstract][Full Text] [Related]
7. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies.
Vera-Ramirez L; Sanchez-Rovira P; Ramirez-Tortosa MC; Ramirez-Tortosa CL; Granados-Principal S; Lorente JA; Quiles JL
Crit Rev Oncol Hematol; 2011 Dec; 80(3):347-68. PubMed ID: 21288735
[TBL] [Abstract][Full Text] [Related]
8. Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
Lazaro G; Smith C; Goddard L; Jordan N; McClelland R; Barrett-Lee P; Nicholson RI; Hiscox S
Endocr Relat Cancer; 2013 Oct; 20(5):691-704. PubMed ID: 23900794
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cells in solid and liquid tissues of breast cancer patients: characterization and therapeutic perspectives.
Chiotaki R; Polioudaki H; Theodoropoulos PA
Curr Cancer Drug Targets; 2015; 15(3):256-69. PubMed ID: 25669721
[TBL] [Abstract][Full Text] [Related]
10. Developmental pathways in breast cancer and breast tumor-initiating cells: therapeutic implications.
Izrailit J; Reedijk M
Cancer Lett; 2012 Apr; 317(2):115-26. PubMed ID: 22123293
[TBL] [Abstract][Full Text] [Related]
11. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen‑ and doxorubicin‑induced autophagy.
Yenigun VB; Ozpolat B; Kose GT
Int J Mol Med; 2013 Jun; 31(6):1477-83. PubMed ID: 23589132
[TBL] [Abstract][Full Text] [Related]
12. Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells.
Guo M; Wang M; Zhang X; Deng H; Wang ZY
Anticancer Res; 2013 May; 33(5):1873-9. PubMed ID: 23645733
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
14. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
15. Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Ito Y; Iwase T; Hatake K
Breast Cancer; 2012 Jul; 19(3):206-11. PubMed ID: 21526426
[TBL] [Abstract][Full Text] [Related]
16. Stem cells in colon cancer.
Pohl A; Lurje G; Kahn M; Lenz HJ
Clin Colorectal Cancer; 2008 Mar; 7(2):92-8. PubMed ID: 18501067
[TBL] [Abstract][Full Text] [Related]
17. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
[TBL] [Abstract][Full Text] [Related]
20. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
